Organon & Co (OGN) Stock

Organon (OGN) closed at $15.06 in the latest trading session, marking a +0.74% move from the prior day.

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Organon is a deep value stock with a high 7.2% yield, supported by a diversified portfolio in women's health, biosimilars, and established pharmaceuticals. Despite stock price volatility, OGN has shown steady performance with growth in adjusted EBITDA and free cash flow. The acquisition of Dermavant and its promising treatment VTAMA for psoriasis and atopic dermatitis could be transformative, expanding OGN's reach into high-demand areas.

In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the acquisition of Dermavant. Organon reported solid Q3 2024 results with 4% revenue growth, driven by strong volume growth more than offsetting pricing weakness and currency headwinds. The $1.2 billion Dermavant acquisition appears strategically acceptable but carries significant risks due to market competition and OGN's high debt.

The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Organon (OGN) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.87 per share a year ago.

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

In the closing of the recent trading day, Organon (OGN) stood at $18.10, denoting a +0.56% change from the preceding trading day.